ASCO 2022 Lymphoma In-Depth

Doctor speaking with male, Asian patient.

Parsaclisib is a Potential Third-Line Therapy for Follicular Lymphoma

CALQUENCE

Acalabrutinib Is Highly Active Chemotherapy-Free Alternative for Marginal Zone Lymphoma

This fact sheet reviews the influence of parent-related factors on pediatric cancer mortality.

Brentuximab Vedotin Improves Outcomes in Pediatric High-Risk Classic Hodgkin Lymphoma

Safety and Efficacy of Sugemalimab in Extranodal Natural Killer/T-Cell Lymphoma

Doctor talking to patient.

Safety and Efficacy of a CD20-CD3-Specific Antibody Therapy for DLBCL

Next post in ASCO 2022 Lymphoma In-Depth

Acalabrutinib Is Highly Active Chemotherapy-Free Alternative for Marginal Zone Lymphoma